152 related articles for article (PubMed ID: 38185741)
1. Immune checkpoint inhibitor-associated colitis in unresectable hepatocellular carcinoma: two cases of early onset after treatment with durvalumab plus tremelimumab.
Abe H; Endo K; Kuroda H; Oikawa T; Abe T; Ito A; Suzuki A; Yoshida Y; Kakisaka K; Matsumoto T
Clin J Gastroenterol; 2024 Apr; 17(2):307-310. PubMed ID: 38185741
[TBL] [Abstract][Full Text] [Related]
2. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
France NL; Blair HA
Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.
Maestri M; Pallozzi M; Santopaolo F; Cerrito L; Pompili M; Gasbarrini A; Ponziani FR
Expert Opin Investig Drugs; 2022 Apr; 31(4):347-360. PubMed ID: 35072571
[TBL] [Abstract][Full Text] [Related]
4. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY; Salem JE; Cohen JV; Chandra S; Menzer C; Ye F; Zhao S; Das S; Beckermann KE; Ha L; Rathmell WK; Ancell KK; Balko JM; Bowman C; Davis EJ; Chism DD; Horn L; Long GV; Carlino MS; Lebrun-Vignes B; Eroglu Z; Hassel JC; Menzies AM; Sosman JA; Sullivan RJ; Moslehi JJ; Johnson DB
JAMA Oncol; 2018 Dec; 4(12):1721-1728. PubMed ID: 30242316
[TBL] [Abstract][Full Text] [Related]
5. Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma.
Song X; Kelley RK; Green M; Standifer N; Lim K; Zhou D; Dunyak J; Negro A; Kurland JF; Ren S; Khan AA; Gibbs M; Abou-Alfa GK
Clin Pharmacol Ther; 2023 Oct; 114(4):874-882. PubMed ID: 37422678
[TBL] [Abstract][Full Text] [Related]
6. An Uncommon Case of Myocarditis Secondary to Durvalumab Plus Tremelimumab.
Diaz-Rodriguez PE; Muns-Aponte CM; Velazquez-Acevedo SI; Ortiz-Malave CM; Acevedo J; Merced-Ortiz FG
Cureus; 2023 Aug; 15(8):e43628. PubMed ID: 37719633
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
8. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Abou-Alfa GK; Lau G; Kudo M; Chan SL; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Dao TV; De Toni EN; Rimassa L; Breder V; Vasilyev A; Heurgué A; Tam VC; Mody K; Thungappa SC; Ostapenko Y; Yau T; Azevedo S; Varela M; Cheng AL; Qin S; Galle PR; Ali S; Gupta C; Makowsky M; Kurland JF; Negro A; Sangro B
Future Oncol; 2023 Dec; 19(38):2505-2516. PubMed ID: 37671641
[TBL] [Abstract][Full Text] [Related]
9. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B; Chan SL; Kelley RK; Lau G; Kudo M; Sukeepaisarnjaroen W; Yarchoan M; De Toni EN; Furuse J; Kang YK; Galle PR; Rimassa L; Heurgué A; Tam VC; Van Dao T; Thungappa SC; Breder V; Ostapenko Y; Reig M; Makowsky M; Paskow MJ; Gupta C; Kurland JF; Negro A; Abou-Alfa GK;
Ann Oncol; 2024 May; 35(5):448-457. PubMed ID: 38382875
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma.
Lim K; Abegesah A; Fan C; He JZ; Song X; Chen C; Negro A; Makowsky M; Gupta C; Ren S; Phipps A; Gibbs M; Zhou D
J Clin Pharmacol; 2023 Nov; 63(11):1221-1231. PubMed ID: 37300457
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
[TBL] [Abstract][Full Text] [Related]
12. Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal.
Kawamura Y; Akuta N; Fujiyama S; Suzuki F; Kumada H
Cureus; 2023 Sep; 15(9):e45385. PubMed ID: 37854758
[TBL] [Abstract][Full Text] [Related]
13. A case of refractory immune checkpoint inhibitor-induced colitis with
Okura Y; Kobayashi K; Yamada Y; Furuya M; Kitano N; Oshina E; Matsuoka M; Nozaka T; Tashiro Y; Sato A; Yauchi M; Matsumoto T; Furumoto Y; Asano T; Azuma S
DEN Open; 2023 Apr; 3(1):e176. PubMed ID: 36262219
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD; Giobbie-Hurder A; Ranasinghe S; Kao KZ; Lako A; Tsuji J; Liu Y; Brennick RC; Gentzler RD; Lee C; Hubbard J; Arnold SM; Abbruzzese JL; Jabbour SK; Uboha NV; Stephans KL; Johnson JM; Park H; Villaruz LC; Sharon E; Streicher H; Ahmed MM; Lyon H; Cibuskis C; Lennon N; Jhaveri A; Yang L; Altreuter J; Gunasti L; Weirather JL; Mak RH; Awad MM; Rodig SJ; Chen HX; Wu CJ; Monjazeb AM; Hodi FS
Lancet Oncol; 2022 Feb; 23(2):279-291. PubMed ID: 35033226
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis.
Fang L; Liu C; Sun X; Liu Z
Front Oncol; 2022; 12():925964. PubMed ID: 35814408
[TBL] [Abstract][Full Text] [Related]
16. Multidisciplinary treatment of a patient with severe immune checkpoint inhibitor-induced colitis: A case report.
Lu L; Sha L; Feng Y; Yan L
World J Clin Cases; 2022 Dec; 10(35):13108-13114. PubMed ID: 36569020
[TBL] [Abstract][Full Text] [Related]
17. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
[TBL] [Abstract][Full Text] [Related]
18. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
[TBL] [Abstract][Full Text] [Related]
19. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
20. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
